The 'stratified' approach to medicine groups patients based on their risk of disease or response to therapy by using diagnostic tests or techniques. The Academy outlined its benefits and made recommendations to aid its widespread development and adoption in its working group report, and continues to explore this area through the FORUM.
‘Stratified medicine’ is the grouping of patients based on risk of disease or response to therapy by using diagnostic tests or techniques.
Patients and healthcare providers both benefit from more targeted and effective treatments, whereas industry benefits from the potential for more efficient therapeutic development as well as the market expansion for these new treatments. These benefits were outlined in the Academy of Medical Sciences' 2007 FORUM symposium report, ‘Optimizing stratified medicines R&D: addressing scientific and economic issues’, which also identified several challenges for the development and adoption of stratified medicine.
These challenges – in the areas of regulation, health economics and clinical and research infrastructure – had not been adequately addressed in the five years to 2012. To ensure these barriers do not persist for a further five years, the Academy initiated work to identify the ongoing challenges and to propose solutions for the development and use of stratified medicine products, namely targeted drugs and their associated diagnostic tests. This project resulted in the 2013 report ‘Realising the potential of stratified medicine’. The Academy released a short film to celebrate the launch of the report.
On November 8 2013, the Academy hosted a follow-up meeting to discuss the implementation of the report‘s recommendations. The meeting brought together key stakeholders to consider relevant plans, progress and opportunities for action, including the identification of short-term gains and long-term goals. A summary note of this meeting is available for download.
Following on from the 2013 report, the Academy recently convened a FORUM symposium in May 2015, together with the Medical Research Council, Science Europe and the University of Southampton, to discuss the ongoing challenges with implementation of stratified medicine. The symposium on 'Stratified, personalised or P4 medicine' highlighted several key challenges to be addressed if the potential of P4 medicine is to be realised. Further information can be found under the '2015 symposium' tab and the meeting report can be downloaded from the righthand side of this page.
The Academy, in partnership with NHS England, has organised a series of FORUM roundtables to explore exemplar clinical pathways for a stratified approach in particular disease areas in the NHS. To date, these roundtables have brought together representatives from across the healthcare sector including commissioning bodies, clinicians, charities, academia and industry, and the discussions from these events will feed directly into NHS England's Personalised Medicine Strategy as well as the Academy's work in this area.
The first roundtable on 8 December 2015explored exemplar clinical pathways for a stratified approach to diabetes and the second roundtable held on 17 March 2016 addressed a stratified approach for cardiovascular disease, specifically focusing on familial hypercholesterolaemia and inherited cardiac conditions such as hypertrophic cardiomyopathy and long QT syndrome. These meetings addressed different aspects of the clinical pathways for stratification including:
Alignment of the diagnostics and therapeutics pathways.
Commissioning and funding frameworks for diagnostics.
A systematic approach to stratification.
Integration of services along the pathway.
Health economics and the strengths and weaknesses of the current evidence base on clinical- and cost-effectiveness.
Engagement and raising awareness
Building capacity and capability.
The reports of both meetings will be published in due course. If you would like to discuss either of these events further then please email firstname.lastname@example.org.
The Academy of Medical Sciences’ FORUM was established in 2003 to catalyse connections across industry, academia and the healthcare sector. Since then, a range of FORUM activities and events have brought together researchers, research funders and research users from across academia, industry, government, and the charity, healthcare and regulatory sectors. Further information and details of future events can be found on the FORUM homepage.
The animation below was developed alongside the 2015 FORUM meeting report on 'Stratified, personalised or P4 medicine'. The animation provides an overview of P4 medicine as well as outlining some of the key themes from the 2015 meeting report.
Following on from the Academy’s 2013 report ‘Realising the potential of stratified medicine’, the Academy convened a one day symposium to discuss the ongoing challenges of implementation of stratified medicines in the healthcare setting.
Consider how the concept of stratified medicines can be applied across the spectrum of diseases, from cancer to rare diseases.
Examine the issues of implementing stratified medicine in healthcare settings.
Look to the future in preparing the healthcare community to embrace this new approach to therapy, including its incorporation into medical education.
The meeting saw over 100 delegates from across Europe – spanning academia, industry, healthcare providers, regulatory and funding bodies – explore the barriers to implementing this evolving approach, and recent developments in data integration and informatics, capacity building, diagnostic development and education. The meeting featured presentations by the 100,000 Genomes project, the Farr Institute in Scotland and the EU IMI initiative, among others (please see the meeting programme for a detailed list of presentations). A series of posters highlighting work by the MRC Stratified Medicine Consortia and by clinicians and academics from the University of Southampton and University Hospital Southampton were also on display.
The symposium highlighted several key challenges that remain to be addressed if the potential of P4 medicine is to be realised. These include the need to:
Better incentivise and reward the development of this approach.
Further integrate and share information and knowledge.
Promote interdisciplinary collaboration.
More closely align medical education and training to the needs of the modern healthcare system.
Encourage and ensure societal acceptance of emerging technologies and approaches.
The speakers' slides and meeting report are available to download from the righthand side of this page.
*P4: Predictive, Preventive, Personalised, and Participatory medicine
This symposium was part of the Academy of Medical Sciences’ FORUM programme of events. The Academy’s FORUM was established in 2003 to recognise the role of industry in medical research, and to catalyse connections across industry and academia. Since then, a range of FORUM activities and events have brought together researchers, research funders and research users from across academia, industry, government, and the charity, healthcare and regulatory sectors. Further information and details of future events can be found on the FORUM homepage.
Stratified, personalised or P4 medicine - FORUM meeting report
The 'Realising the potential of stratified medicine' report arose from a project that followed on from the Academy’s 2007 report, undertaken to facilitate progress in stratified medicine research and development, and the implementation of these approaches in healthcare services.
The project focused on identifying solutions to the ongoing barriers in clinical and research infrastructure, regulation and pricing and reimbursement. To discuss the issues at an October 2012 symposium, the project brought together experts from the pharmaceutical and diagnostic industries, health economists, medicines regulators, health service providers, clinical researchers and policy makers in the private and public sectors.
The report draws on the following: the four discussion papers prepared for the symposium, which defined challenges and suggested solutions; discussions at the symposium; case studies, which set out the drug and/or diagnostic development pathways used by industry and drew out the lessons learnt; and the expertise of the oversight group. It tackles global issues, but because members of the preparatory groups and symposium attendees were mostly from the UK, does so largely from a UK and European perspective.
Overall the report concludes that:
Collection, analysis and use of biomedical and health data should be enhanced;
Changes to regulation and pricing systems are required as they currently do not provide adequate incentives for the development of stratified medicine products;
Influencing clinical practice will be critical for stratified medicine to be embedded in healthcare; and
Collaboration will be crucial to accelerate the development and adoption of stratified medicine.
The Academy is grateful for the support of Amgen, the Association of the British Pharmaceutical Industry, GE Healthcare, the Medical Research Council, the Medicines and Healthcare products Regulatory Agency, Roche and the Technology Strategy Board.
Oversight and review groups for 2013 report
The Academy appointed an oversight group to lead the 2013 'Realising the potential of stratified medicine' project.
Job titles and affiliations were correct at the time of the symposium (10–11 October 2012)
Professor Sir John Bell FRS HonFREng FMedSci Regius Professor of Medicine, University of Oxford (Chair)
Dr Richard Barker Director, Centre for the Advancement of Sustainable Medical Innovation
Dr Graham Bell Lead Technologist in Stratified Medicine, Technology Strategy Board
Professor Lou Garrison Associate Director of the Pharmaceutical Outcomes Research and Policy Program, University of Washington
Dr Jeremy Haigh European Chief Operating Officer, Research & Development, Amgen Ltd
Dr Louise Leong Head of R&D, The Association of the British Pharmaceutical Industry
Dr Tom Lillie International Therapeutic Area Head for Oncology, Amgen Ltd
Dr Thomas Lönngren Strategic Advisor, NDA Advisory Service Ltd
Dr Iain Miller Global Head of Personalized Healthcare Strategy and Partnerships, GE Healthcare
Professor Andrew Morris FRSE FMedSci Professor and Dean of Medicine, University of Dundee and Chief Scientist for Health in Scotland
Professor Adrian Towse Director, Office of Health Economics
Dr Desmond Walsh Head of Infections and Immunity and Lead for Stratified Medicine, Medical Research Council
Members participating before the symposium:
Mr Daniel O’Day Chief Operating Officer, Roche Pharmaceuticals
Sir Kent Woods FMedSci Chief Executive, Medicines and Healthcare products Regulatory Agency
The 2013 report was reviewed by an external panel appointed by the Council of the Academy of Medical Sciences. Reviewers were asked to consider whether the report met the terms of reference, and whether the evidence and arguments presented in the report were sound and supported the conclusions. Reviewers were not asked to endorse the report or its findings.
Job titles and affiliations were correct at the time of report review (March - April 2013)
Professor Susan Iversen CBE FMedSci Emeritus Professor of Psychology, University of Oxford and Treasurer of the Academy of Medical Sciences (Chair)
Professor Sir Alasdair Breckenridge CBE FRSE FMedSci Formerly Chair of the Medicines and Healthcare products Regulatory Agency
Professor Anthony Culyer CBE FMedSci Professor of Economics, University of York and Ontario Chair in Health Policy and System Design at the University of Toronto
Professor Christopher Day FMedSci Pro-Vice-Chancellor of the Faculty of Medical Sciences and Professor of Liver Medicine, Newcastle University